Terumo Neuro in the News

Nov 15, 2024

Orange County Business Journal

Terumo Neuro Debuts New Name, Expanded HQ

Orange County Business Journal highlights transformation to Terumo Neuro and the expansion of Aliso Viejo headquarters. This milestone reflects their commitment to advancing neurovascular innovation and enhancing patient outcomes worldwide. Read the full article here!

Sep 12, 2024

Associated Press

MicroVention Rebrands to Terumo Neuro – Reflects Expanded Focus and Strategic Growth

MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care.

Sep 12, 2024

Interventional News

Microvention officially rebrands to Terumo Neuro, reflecting “expanded focus and strategic growth”

Microvention, a wholly owned subsidiary of Terumo Corporation, has today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialisation of groundbreaking innovations in neurovascular care, as stated in a press release.

Sep 12, 2024

Yahoo! Finance

MicroVention Rebrands to Terumo Neuro – Reflects Expanded Focus and Strategic Growth

MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care.

Sep 12, 2024

Neuro News

Microvention officially rebrands to Terumo Neuro, reflecting “expanded focus and strategic growth”

Microvention, a wholly owned subsidiary of Terumo Corporation, has today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialisation of groundbreaking innovations in neurovascular care, as stated in a press release.

Sep 12, 2024

Mass Device

MicroVention rebrands to Terumo Neuro

MicroVention, a Terumo subsidiary, today announced its official rebranding to Terumo Neuro, effective immediately. The company says the name change signifies a new chapter in its evolution while maintaining its commitment to neurovascular care.

Sep 12, 2024

AFP

MicroVention passa a se chamar Terumo Neuro – A mudança reflete o foco ampliado e o crescimento estratégico

A MicroVention, Inc., líder global em inovação neurovascular e subsidiária integral da Terumo Corporation, anunciou hoje sua mudança de nome oficial para Terumo Neuro, com efeito imediato. Essa mudança de nome simboliza um novo capítulo na evolução da empresa, mantendo seu compromisso inabalável com a criação e comercialização de inovações revolucionárias no cuidado neurovascular.

Aug 21, 2024

Medical Product Outsourcing

Study: MicroVention's WEB 17 System Just as Safe, Effective as Previous Versions

MicroVention Inc. is spotlighting published study results proving the efficacy of its WEB 17 system. Data from the CLinical EValuation of WEB 17 Device in Intracranial Aneurysms (CLEVER) trial showed the WEB 17's efficacy is equivalent to previous versions of the device. The study evaluated the WEB 17 system in ruptured and unruptured aneurysms to better understand its safety and efficacy.

Jul 17, 2024

Medical Device Network

California court sides with MicroVention in stolen trade secrets trial

The California court has ordered three defendants to make up for losses to the company after three former employees disclosed trade secrets to a competitor.

Jul 9, 2024

Endovascular Today

MicroVention’s Sofia 6-F Aspiration System Studied in SOFAST as a First-Line Technique for AIS

July 9, 2024—MicroVention, Inc., a neurovascular company and wholly owned subsidiary of Terumo Corporation, announced the publication of findings from the SOFAST study.

Jul 9, 2024

NeuroNews

Microvention announces publication of SOFAST clinical data

Microvention, a wholly owned subsidiary of Terumo Corporation, has today announced the publication of data from SOFAST—a prospective, multicentre US study assessing the efficacy and safety of the 6Fr Sofia flow plus aspiration catheter as a first-line endovascular stroke thrombectomy technique. Findings from the study have been published in the Journal of NeuroInterventional Surgery (JNIS).

Jul 9, 2024

BioSpace

MicroVention Announces Clinical Publication of SOFAST: SOFIA™ Aspiration System as First Line Technique in Treating Acute Ischemic Stroke

SOFIA™ Aspiration Catheters Have Continued to Set the Standard for Over 10 Years with Renowned Trackability, Speed and Proven Clinical Performance

Jun 27, 2024

Medical Device Network

MicroVention announces commercial availability of LVIS EVO device in US

Terumo subsidiary and neurovascular company MicroVention has announced the commercial availability of the LVIS EVO Intraluminal Support Device in the US.

Jun 27, 2024

Mass Device

MicroVention launches new stent in the U.S.

Terumo subsidiary MicroVention announced that it began the U.S. launch for its LVIS EVO intraluminal support device.

Jun 26, 2024

NeuroNews

Microvention announces US availability of LVIS EVO intraluminal support device

Microvention, a wholly owned subsidiary of Terumo Corporation, announced today that the LVIS EVO intraluminal support device is now commercially available for the treatment of wide-neck intracranial aneurysms in the USA.

Jun 26, 2024

Endovascular Today

MicroVention’s LVIS EVO Intraluminal Support Device Launched in US

June 26, 2024—MicroVention, Inc. announced that its LVIS EVO intraluminal support device is commercially available in the United States for the treatment of wide-neck intracranial aneurysms.

Jun 26, 2024

BioSpace

MicroVention Announces the Next Evolution in Stent Innovation: MicroVention’s LVIS™ EVO™ Intraluminal Support Device Now Available in the United States

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the LVIS™ EVO™ Intraluminal Support Device is now commercially available in the United States for the treatment of wide neck intracranial aneurysms.

Apr 29, 2024

Orange County Business Journal

MicroVention Buys PacLife Building for $44M

MicroVention Terumo, Orange County’s seventh largest medical device maker by local employee count, is undertaking an aggressive expansion. The Aliso Viejo-based maker of stroke treatments last month paid Pacific Life Insurance Co. $44 million for a 242,706-square-foot office tower in its home city at 45 Enterprise.

Sep 21, 2023

NeuroNews

Microvention enters transradial access market with US FDA clearance of Sofia EX catheter

Microvention, a wholly owned subsidiary of Terumo Corporation, announced today that the Sofia EX 5Fr 115cm intracranial support catheter received US Food and Drug Administration (FDA) 510(k) clearance on 15 September 2023 for use in transradial access in addition to transfemoral access.

Sep 21, 2023

Endovascular Today

MicroVention Sofia EX 5-F, 115-cm Intracranial Support Catheter Cleared for Transradial Access

MicroVention, Inc., a neurovascular company and wholly owned subsidiary of Terumo Corporation, announced that the Sofia EX 5-F, 115-cm intracranial support catheter has received FDA 510(k) clearance for transradial access in addition to transfemoral access.

Sep 21, 2023

CardiacVascular News

MicroVention Enters Transradial Access Therapy; Receives FDA Clearance of SOFIA™ EX 5F 115cm Intracranial Support Catheter

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the SOFIA™ EX 5F 115 cm Intracranial Support Catheter (Soft TOrqueable catheter For Intracranial Access) has received FDA 510(k) clearance on September 15, 2023, for transradial access in addition to transfemoral access.

Sep 12, 2023

NeuroNews

New Pathway to Neurosurgery programme intends to “open doors” for underrepresented groups

The Congress of Neurological Surgeons (CNS) Foundation has launched its Pathway to Neurosurgery programme, an initiative dedicated to alleviating healthcare disparities by encouraging high school students from underrepresented groups to pursue a career in neurosurgery or medicine.

Sep 8, 2023

Associated Press News

Groundbreaking Program Encourages Underrepresented Minorities to Consider Career in Neurosurgery

WASHINGTON, Sept. 8, 2023 /PRNewswire/ -- Today, the Congress of Neurological Surgeons (CNS) Foundation launched its Pathway to Neurosurgery program in Washington, DC. The initiative is dedicated to alleviating health care disparities by encouraging high school students from underrepresented groups to pursue a career in neurosurgery or medicine.

Aug 23, 2023

Neuro News

Continued improvement of flow diverters and intrasacculars holds key to truly advancing aneurysm care

Laurent Pierot’s (Reims University Hospitals, Reims, France) long career in the treatment of intracranial aneurysms predates not only what many consider to be the advent of the interventional neuroradiology (INR) specialty, the ISAT trial, but also the introduction of the Guglielmi detachable coil (GDC) in 1990.

Jul 31, 2023

Endovascular Today

MicroVention Announces New Sizes of Web System and 5-Year WEB-IT Trial Data

MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced the addition of two sizes to its Web aneurysm embolization system. The Web system is now available in single-layer (SL) 6 X 2 mm and SL 7 X 2 mm sizes, which allow for the treatment of different sizes and shapes of aneurysms.

Jul 31, 2023

Yahoo!Finance

MicroVention Announces 5-Year Clinical Trial Data and Size Additions for its WEB Aneurysm Embolization System; WEB is Most Well-Studied Intrasaccular Device Available Today

MicroVention’s WEB System is the World Leader and Only PMA-Approved Intrasaccular Flow Disruptor; Advances Treatment of Wide-Neck Bifurcation Aneurysms with ONE Device

Jul 31, 2023

Medical Buyer

MicroVention celebrates one-year anniversary of FRED X Flow Diverter

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, is celebrating the one-year anniversary of the company’s FRED™ X Flow Diverter. In close collaboration with physician partners across the United States, over 1,000 patients have been successfully treated with the FRED X device.

Jul 31, 2023

Bloomberg

MicroVention Celebrates One-Year Anniversary of FRED™ X Flow Diverter with Over 1,000 Patients Treated Across the U.S.

MicroVention Celebrates One-Year Anniversary of FRED™ X Flow Diverter with Over 1,000 Patients Treated Across the U.S. The FRED X Flow Diverter is the Next Generation in Flow Diversion Technology

Jul 31, 2023

NeuroNews

Microvention announces five-year WEB-IT data alongside two new device sizes

Microvention, a wholly owned subsidiary of Terumo Corporation, has announced the publication of five-year follow-up data from the WEB-IT trial and the addition of two sizes to its Woven EndoBridge (WEB) aneurysm embolisation system.

Jun 28, 2023

Endovascular Today

MicroVention Launches Eric Retrieval Device for Ischemic Stroke Treatment in United States

The Eric device joins a portfolio of stroke solutions from MicroVention including the Sofia catheter, Bobby balloon guide catheter, Wedge and Headway microcatheters, and Traxcess guidewire.

Jun 28, 2023

Medical Device Network

MicroVention announces commercial availability of ERIC device in US

Terumo’s wholly owned subsidiary MicroVention has announced the commercial availability of its ERIC Retrieval Device in the US for ischemic stroke treatment.

Jun 27, 2023

Yahoo Finance

MicroVention Reshapes Stroke Therapy with the Introduction of the ERIC™ Retrieval Device; ERIC Delivers Thrombus Control, Procedure Efficiency and Versatility When Every Second Counts

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the ERIC Retrieval Device is now commercially available in the United States for ischemic stroke treatment.

Jun 27, 2023

Cardiac Vascular News

MicroVention Reshapes Stroke Therapy with the Introduction of the ERIC™ Retrieval Device; ERIC Delivers Thrombus Control, Procedure Efficiency and Versatility When Every Second Counts

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the ERIC Retrieval Device is now commercially available in the United States for ischemic stroke treatment. ERIC received FDA 510(k) clearance on March 31, 2022.

May 23, 2023

NeuroNews

WEB 17 device maintains efficacy, safety across ruptured and unruptured aneurysms

The WEB 17 device has demonstrated positive efficacy and safety outcomes in the prospective, multicentre CLEVER study, indicating its utility for intrasaccular embolisation across ruptured and unruptured intracranial aneurysms. Twelve-month results from the study were recently delivered by Laurent Spelle (Bicêtre Hospital, Paris, France) at the LINNC Americas Seminar (16–17 March, Miami, USA).

Apr 11, 2023

MicroVention Announces Continued Achievements with its Door to the Future Program with the Republic of Costa Rica; President Rodrigo Chaves Robles Signs National Employment Program Decree at MicroVention Today and Tours Door to the Future Lab

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today hosted the Republic of Costa Rica’s President Rodrigo Chaves Robles and other government officials and dignitaries at its Costa Rica facility in Alajuela.

Apr 11, 2023

The Associated Press

MicroVention Announces Continued Achievements with its Door to the Future Program with the Republic of Costa Rica; President Rodrigo Chaves Robles Signs National Employment Program Decree at MicroVention Today and Tours Door to the Future Lab

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today hosted the Republic of Costa Rica’s President Rodrigo Chaves Robles and other government officials and dignitaries at its Costa Rica facility in Alajuela.

Dec 16, 2022

NeuroNews

How do we improve the treatment of stroke patients in the future?

Since its inception in 1997, MicroVention has gradually expanded its offerings from cerebral aneurysms to include several other areas in neuroendovascular care—with ischaemic stroke being a key area of focus over the past 15 years.

Sep 29, 2022

NeuroNews

Microvention celebrates 25 years in neuroendovascular technologies with ‘Patient’s Day’

Microvention, a wholly owned subsidiary of Terumo Corporation, today celebrated its 25-year anniversary in the neuroendovascular technologies industry.

Aug 15, 2022

NeuroNews

SNIS 2022: WEB flow diverter shown to be safe and effective in long-term cohort

The Society of NeuroInterventional Surgery’s19th annual meeting saw research involving the Woven EndoBridge (WEB; Microvention/Terumo) device disclosed for the first time, with co-principal investigator Adam Arthur (University of Tennessee Health Sciences Center and Semmes-Murphey Clinic, Memphis, USA) delivering a late-breaking presentation of five-year data from the WEB-IT trial.

Jun 13, 2022

NeuroNews

Multicentre study indicates WEB flow disrupters can safely be used in sidewall aneurysms

As per the findings of a multicentre, retrospective study, use indications for the Woven EndoBridge (WEB) intrasaccular flow disruption device (Microvention/Terumo) can be safely extended to include sidewall intracranial aneurysms.

Apr 22, 2022

Society of NeuroInterventional Surgery

MicroVention Announces First Patient Enrolled in the STRAIT Study with the New BOBBY™ Balloon Guide Catheter

MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced the successful completion of its first enrollment in a multi-center, prospective EU observational study called STRAIT, to evaluate the Safety and Performance of the BOBBY Balloon Guide Catheter for Endovascular Treatment of Acute Ischemic Stroke.